How to Sequence Therapies in Peripheral T Cell Lymphoma.
Opinion Statement: Peripheral T cell lymphoma (PTCL) represents a heterogeneous group of rare lymphoproliferative disorders. Historically, there has been a lack of pathobiological understanding of PTCL. With the exception of ALK-positive anaplastic large cell lymphoma, patients with PTCL have less f...
| Publicado en: | Current Treatment Options in Oncology Vol. 22; no. 9; pp. 1 - 17 |
|---|---|
| Autores principales: | , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Sep2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151961038&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 151961038 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Sep2021 vid: 22 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 151961038 151961038 NLM34213653 151961038 10.1007/s11864-021-00873-w NLM34213653 151961038 ppf: 1 ppct: 16 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: How to Sequence Therapies in Peripheral T Cell Lymphoma. aug: au: Wudhikarn, Kitsada Bennani, N. Nora affil: Division of Hematology, Department of Medicine, Mayo Clinic, 55905, Rochester, MN, USA sug: subj: Lymphoma, T-Cell Therapy Neoplasm Grading Lymphoma, T-Cell Diagnosis Disease Susceptibility Treatment Outcomes Recurrence Neoplasm Staging Algorithms Disease Management Repeat Procedures Lymphoma, T-Cell Mortality Decision Trees Drug Resistance, Neoplasm Prognosis Combined Modality Therapy Adverse Effects Lymphoma, T-Cell Etiology Combined Modality Therapy Methods ab: Opinion Statement: Peripheral T cell lymphoma (PTCL) represents a heterogeneous group of rare lymphoproliferative disorders. Historically, there has been a lack of pathobiological understanding of PTCL. With the exception of ALK-positive anaplastic large cell lymphoma, patients with PTCL have less favorable outcomes, with most patients relapsing shortly after conventional anthracycline-containing multi-agent chemotherapy. The standard management approach for PTCL involves induction therapy followed by autologous stem cell transplantation. Patients with relapsed/refractory PTCL have dismal outcomes and limited treatment options despite the available novel agents, therefore remaining a critical unmet need. By virtue of advancement in cancer biology over the recent years, the treatment landscape of PTCL has gradually evolved from conventional chemotherapy based on solely morphological diagnosis toward more individualized therapies by integrating molecular attributes of PTCL to the traditional treatment paradigm. We are at the edge of witnessing a paradigm shift in PTCL management. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|